Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Appili Therapeutics Inc. (APLIF : OTC)
 
 • Company Description   
Appili Therapeutics Inc. is a biopharmaceutical company. It acquires, develops and commercializes novel medicines for unmet needs in the infectious disease. The company's lead product consist ATI-2307, ATI-1501 and ATI-1701 which are in clinical stage. Appili Therapeutics Inc. is based in Halifax, Canada.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.01 Daily Weekly Monthly
20 Day Moving Average: 22,905 shares
Shares Outstanding: 121.27 (millions)
Market Capitalization: $1.08 (millions)
Beta: -0.58
52 Week High: $0.03
52 Week Low: $0.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -27.05% -30.06%
12 Week -57.82% -63.04%
Year To Date -68.21% -69.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
21-1344 SUMMER ST.
-
HALIFAX,A5 B3H 0A8
CAN
ph: 902-442-4655
fax: -
None http://www.appilitherapeutics.com
 
 • General Corporate Information   
Officers
Don Cilla - President and Chief Executive Officer
Armand Balboni - Chairman
Kenneth Howling - Acting Chief Financial Officer
Art Baran - Director
Carl Gelhaus - Director

Peer Information
Appili Therapeutics Inc. (CORR.)
Appili Therapeutics Inc. (RSPI)
Appili Therapeutics Inc. (CGXP)
Appili Therapeutics Inc. (BGEN)
Appili Therapeutics Inc. (GTBP)
Appili Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03783R107
SIC: 2834
Fiscal Year
Fiscal Year End: March
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 121.27
Most Recent Split Date: (:1)
Beta: -0.58
Market Capitalization: $1.08 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 100.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -78.37%
vs. Previous Quarter: 2,466.67%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -134.60
12/31/24 - -203.73
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 0.14
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 0.14
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -0.08
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©